Abstract:Background: Sorafenib is the first FDA approved first-line targeted drug for advanced HCC. However, resistance to sorafenib is frequently observed in clinical practice, and the molecular mechanism remains largely unknown. This study aimed to clarify the mechanism of sorafenib resistance and seek more effective treatments for HCC.Methods: Two sorafenib-resistant (SR) cell lines were established by continuous exposure to sorafenib. Global transcriptional consequences of sorafenib-resistant HCC was characterized, and immunoprecipitation-mass spectrometry (IP-MS) was performed to identify specific acetylation sites.Findings: PLEKHG5 was abundantly up-regulated in HCC patients and sorafenib-resistant cells, which was correlated with poor outcomes in HCC patients. PLEKHG5 overexpression activated the Rac1/AKT/NF-κB signaling and reduced sensitivity to sorafenib in HCC cells, while knockdown of PLEKHG5 increased sorafenib sensitivity. Histone deacetylase 2 (HDAC2) was directly interacted with PLEKHG5 to deacetylate its lysine sites within the PH domain and consequently maintain its stability. Moreover, HDAC2 inhibition (HDAC2 knockout or inhibitor) induced PLEKHG5 acetylation-related degradation and thereby enhanced the sensitivity of HCC to sorafenib in vitro and in vivo.Interpretation: Our work showed a novel mechanism for maintaining sorafenib resistance by HDAC2-mediated PLEKHG5 posttranslational modifications, and is a proof-of-concept study for targeting HDAC2 and PLEKHG5 in sorafenib-treated HCC patients as a new pharmaceutical intervention for advanced HCC.Funding Information: This work was supported by grants from the National Natural Science Foundation of China (no. 81602045; no. 81802454; no. U20A20392), the Basic and frontier research project of Yuzhong District, Chongqing (no. 20180118), and the Natural Science Foundation Project of Chongqing (no. cstc2016jcyjA0206). Declaration of Interests The authors declare that they have no competing interests.Ethics Approval Statement: The Institute Research Medical Ethics Committee of First Affiliated Hospital of Chongqing Medical University (Chongqing, China) granted approval for this study. At the time of tissue collection, informed consent was obtained from all patients.

Sorafenib-mediated cleavage of p62 initiates cellular senescence as a mechanism to evade its anti-hepatocellular carcinoma efficacy

The Up-Regulation of P62 Levels is Associated with Resistance of Sorafenib in Hepatocarcinoma Cells.

Abstract A155: Activation of PI3K/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.

Sorafenib-Mediated Targeting of the Aaa(+) Atpase P97/Vcp Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death

Activation of Phosphatidylinositol 3-Kinase/akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells

Sorafenib induces cachexia by impeding transcriptional signaling of the SET1/MLL complex on muscle-specific genes

Sorafenib triggers ferroptosis via inhibition of HBXIP/SCD axis in hepatocellular carcinoma

UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma

Sorafenib-Induced Autophagy Promotes Glycolysis by Upregulating the p62/HDAC6/HSP90 Axis in Hepatocellular Carcinoma Cells

Dual inhibition of CDK4/6 and XPO1 induces senescence with acquired vulnerability to CRBN-based PROTAC drugs

Sorafenib Suppresses Growth and Survival of Hepatoma Cells by Accelerating Degradation of Enhancer of Zeste Homolog 2

Inhibitors of the protein–protein interaction between phosphorylated p62 and Keap1 attenuate chemoresistance in a human hepatocellular carcinoma cell line

Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant hep G2 cells through a mitochondria-dependent oxidative stress mechanism

Targeting KDM1A Attenuates Wnt/β-catenin Signaling Pathway to Eliminate Sorafenib-Resistant Stem-Like Cells in Hepatocellular Carcinoma.

PLEKHG5, Stabilized by HDAC2-Related Deacetylation, Confers Sorafenib Resistance Through Regulating Rac1/AKT/NF-κB Signaling in HCC

Sorafenib induces ferroptosis by promoting TRIM54-mediated FSP1 ubiquitination and degradation in hepatocellular carcinoma

CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death

DDX39B protects against sorafenib-induced ferroptosis by facilitating the splicing and cytoplasmic export of GPX4 pre-mRNA in hepatocellular carcinoma

Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.

SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma